Sana Biotechnology (SANA) AI Stock Analysis

• Market Cap: $633.81M
• Dividend Yield: N/A
• Average Volume (3M): 4.67M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: N/A
• EPS Growth: 19.94%
• Country: US
• Employees: 194
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 225,555,370
• 10 Day Avg. Volume: 6,173,965
• 30 Day Avg. Volume: 4,669,598
• PEG Ratio: -0.06
• Price to Book (P/B): -46.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -58.88
• Enterprise Value/Market Cap: 10.32
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.68K
• Enterprise Value/Ebitda: -6.84
• 1Y Price Target: $9.25
• Price Target Upside: 226.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 33 Underperform
• Price Target: ―

Sana Biotechnology's overall stock score is primarily impacted by significant financial challenges, including consistent losses and a lack of revenue. Despite some improvements in balance sheet stability and operating cash flow, the bearish technical indicators and negative valuation metrics underscore the need for strategic changes to achieve growth and profitability.

Positive Factors

Research and Development

The GLEAM and VIVID trials are on track for data in 2025, indicating progress in Sana's research and development efforts.

Scientific Validation

The sustained safety and efficacy profile of UP421 is highly encouraging as it continues to provide in-human results that validate Sana's HIP-technology.

Technological Advantage

Sana's HIP-modified islet cell therapy is differentiated from peers as it does not require the use of immunosuppression, unlike other islet cell therapies in development.

Negative Factors

C-Peptide Levels

Some investors note that the C-peptide levels were significantly lower than normal levels and therefore not enough for the patients to achieve insulin independence.

Financial Performance

Sana reported a Q1 loss of $49.4MM, raising concerns about its financial performance.

Sana Biotechnology Business Overview & Revenue Model

Company Description

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

How the Company Makes Money

Sana Biotechnology makes money primarily through the development and commercialization of its proprietary cell engineering platforms and technologies. The company generates revenue through partnerships and collaborations with other biotech and pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies. Additionally, Sana may earn revenue from government grants and research funding, as well as potential future sales of approved therapeutic products. Strategic collaborations and licensing agreements are significant contributors to Sana's earnings, enabling the company to leverage its innovative technologies for broader applications and market reach.

Sana Biotechnology Financial Statement Overview

Summary

Sana Biotechnology faces substantial financial challenges, primarily due to its lack of revenue and consistent losses. While there are signs of improvement in balance sheet equity and operating cash flow management, the company needs to focus on generating revenue and achieving profitability to ensure long-term viability. The reliance on external financing is a potential risk if not supported by future revenue growth.

Income Statement

Sana Biotechnology has not generated any revenue over the past years, leading to consistent negative gross and net profit margins. The company reports significant losses in EBIT and EBITDA, reflecting challenges in achieving profitability. The lack of revenue growth indicates a need for strategic adjustments to capture market opportunities.

Balance Sheet

The company's balance sheet shows moderate stability with a debt-to-equity ratio of 0.38 in 2024. However, the equity ratio of approximately 50% suggests a balanced but slightly leveraged position. The negative equity in previous years has improved, indicating some progress, but the overall financial health remains fragile.

Cash Flow

Sana Biotechnology's cash flow reflects significant negative free cash flow, though there is a slight improvement in operating cash flow relative to net income. The company heavily relies on financing activities, which poses sustainability concerns if revenue generation does not improve.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.90M	0.00	-30.86M	-27.73M	-17.91M	-10.17M
EBITDA	-193.54M	-251.27M	-252.39M	-256.94M	-345.84M	-287.03M
Net Income	-208.67M	-266.76M	-283.25M	-269.48M	-355.93M	-285.31M
Balance Sheet
Total Assets	445.47M	501.02M	565.30M	822.72M	1.13B	730.30M
Cash, Cash Equivalents and Short-Term Investments	104.70M	152.50M	205.19M	434.01M	746.88M	412.00M
Total Debt	91.31M	94.20M	104.10M	108.25M	110.94M	71.91M
Total Liabilities	236.39M	250.52M	277.79M	323.40M	400.90M	1.15B
Stockholders Equity	209.08M	250.50M	287.51M	499.31M	728.50M	-421.18M
Cash Flow
Free Cash Flow	-223.90M	-256.58M	-273.61M	-310.93M	-280.92M	-161.85M
Operating Cash Flow	-206.18M	-223.15M	-253.58M	-290.05M	-251.05M	-137.98M
Investing Cash Flow	111.28M	17.45M	172.01M	210.56M	-245.80M	-252.56M
Financing Cash Flow	14.33M	199.75M	31.65M	4.91M	631.75M	435.69M

Sana Biotechnology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SANA, the sentiment is Positive. The current price of 2.83 is above the 20-day moving average (MA) of 2.70, above the 50-day MA of 2.21, and above the 200-day MA of 2.72, indicating a bullish trend. The MACD of 0.17 indicates Positive momentum. The RSI at 59.33 is Neutral, neither overbought nor oversold. The STOCH value of 38.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SANA.

Sana Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	€4.84B	18.30	-49.50%	1.94%	13.92%	-4.82%
XERS	54 Neutral	$746.32M	―	222.83%	―	29.88%	35.11%
AUTL	53 Neutral	$609.46M	―	-49.97%	―	-14.16%	25.80%
DNTH	46 Neutral	$566.98M	―	-28.73%	―	189.31%	51.03%
TECX	42 Neutral	$369.72M	―	-30.10%	―	―	-343.40%
SANA	33 Underperform	$633.81M	―	-71.44%	―	―	19.94%
HYREQ		$31.00	―		―	―	―

Sana Biotechnology Corporate Events

Sana Biotechnology Shows Promise with Hypoimmune Platform

Sana Biotechnology announced promising results from its hypoimmune platform (HIP) that show potential in overcoming allogeneic and autoimmune rejection, notably in type 1 diabetes. The company’s approach, which addresses a significant limitation in transplant medicine, could transform treatment options for various diseases, enhancing its industry positioning and offering new hope for patients with unmet medical needs.